NASHVILLE, Tenn.–(BUSINESS WIRE)–PureEHS today announced an expanded investment in the PureSafety training content portfolio, reinforcing its commitment to one of the industry’s most trusted safety training brands. For decades, employers have relied on PureSafety for high-quality safety, compliance, and OSHA-authorized training aligned with industry best practices. As part of PureEHS, the brand continues to grow with new investments in content development, accessibility, learner experience, a
Month: September 2026
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
Access it here
OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing how Ampligen® (rintatolimod) could fit into the evolving treatment landscape for pancreatic cancer.
In the CEO Corner, Equels discusses recent advances in pancreatic cancer treatment and why AIM believes Ampligen’s distinct immune-modulating approach warrants continued investigation. Rather than directly targeting a cancer-driving pathway, Ampligen has the potential to induce a broad-spectrum therapeutic effect that amplifies a patient’s innate immune response, creating the potential for a complementary role alongside or following therapies that act through different mechanisms.
The segment also highlights observations from a Dutch Named Patient Program (“NPP”) in which patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (“NLR”) below 4.5, median overall survival was 34.8 months, measured from the start of FOLFIRINOX. This encouraging observation supports further investigation of Ampligen following chemotherapy.
Advances with FOLFIRINOX and daraxonrasib highlight the evolving treatment landscape in pancreatic cancer. The following chart summarizes the median overall survival results from the selected patients from NPP program as well as data from the separate clinical trials of FOLFIRINOX in metastatic pancreatic cancer and a daraxonrasib clinical trial of RAS G12 mutation patients with previously treated metastatic pancreatic cancer.
However, differences in patient selection, disease stage, treatment setting, and the timing of survival measurement prevent direct comparisons between the NPP findings and survival results from trials of these therapies. These findings provide a rationale for randomized studies to determine whether adding Ampligen after chemotherapy improves outcomes. Further research is also needed to establish whether NLR can identify patients more likely to benefit specifically from Ampligen, rather than patients with a generally more favorable prognosis.
“Pancreatic cancer continues to present an urgent need for better treatment strategies, even as important new therapies emerge,” said Equels. “Ampligen approaches the disease differently through its potential to activate the innate immune response. We believe the powerful overall survival signal seen in the Named Patient Program, together with the clinical and biomarker data being generated through DURIPANC, will provide a compelling rationale to continue evaluating Ampligen’s potential role in pancreatic cancer. Ultimately, our goal is to get drug approval, which will be based on overall survival, in all probability focused on patients with neutrophil-to-lymphocyte ratios below 4.5.”
AIM is continuing to investigate Ampligen through the ongoing Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca’s durvalumab in metastatic pancreatic cancer. The study’s primary endpoint is Clinical Benefit Rate at 24 weeks following initiation of combination therapy, with topline results anticipated in the first quarter of 2027. The study is also evaluating progression-free survival, overall survival and immune profiling, with overall survival analysis expected to begin in 2027.
AIM anticipates topline results from DURIPANC in the first quarter of 2027, followed by its analysis of overall survival – the gold standard for drug approval – commencing in Q3 2027. If supported by the clinical and biomarker data, the Company believes the study could help define the parameters of a potential follow-up pivotal Phase 3 program and provide positive clarity around where Ampligen fits within an evolving pancreatic cancer treatment landscape.
The latest CEO Corner segment is now available on the Company’s website here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: Ampligen’s potential efficacy and applicability in the treatment of pancreatic cancer; the timing of commencement, enrollment, completion, and results of clinical trials; intellectual property expansion and regulatory progress; and timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of pancreatic cancer. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/32219329-21da-4057-bdc6-8fb8989db060
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
A new joint venture focused on the localisation of self-propelled howitzer production is to be established during 2026 and start production in 2027. Over a seven-year period, the project represents a business opportunity worth EUR 1.8 billion.
On the occasion of the international ADEX defence exhibition in Baku, CSG group announced its intention to establish its second joint venture in Azerbaijan. The new company, created with a local partner, will focus on the gradual localisation of self-propelled howitzer production and the related transfer of CSG technologies and production know-how to Azerbaijan.
According to the current schedule, the joint venture is to be established in December 2026, while the start of production is planned for 2027. According to the current medium-term plan, the project represents a business opportunity worth EUR 1.8 billion over the next seven years. With regard to the agreed confidentiality arrangements, CSG is not disclosing the specific types of self-propelled howitzers, the planned production volumes or the identity of the local partner.
The new project follows the long-term development of CSG’s industrial activities in Azerbaijan and the first joint venture, VEXA DS, LLC, whose establishment the group announced in April 2026. VEXA DS focuses on the repair, servicing and modernisation of armoured vehicles and other land military equipment in Azerbaijan. The programme of this joint venture includes hundreds of pieces of equipment with a total value in the hundreds of millions of euros and an expected duration of ten years or more.
Azerbaijan is one of the markets where CSG is systematically building a long-term industrial presence combining production, servicing, modernisation and technology transfer. The planned second joint venture further develops this strategy: instead of a model based only on the export of finished products, CSG will combine its own technologies and know-how with gradually developed local production capacities and a long-term industrial partnership.
“The signing of agreements leading to the establishment of our second joint venture in Azerbaijan confirms that we are building a long-term industrial presence here. After servicing and modernisation of land military equipment, we are now expanding our cooperation to include the localisation of production. The project, with business potential of EUR 1.8 billion over the next seven years, represents a significant long-term opportunity for CSG. At the same time, our model is not based only on the export of finished products, but on a combination of our own technologies, local production, know-how transfer and long-term industrial partnership,” said Jan Marinov, CEO of the CSG Defence Systems division.
The localisation of production will take place gradually in several phases. CSG will bring its technological and production know-how in the field of land artillery systems to the project and will participate in the gradual development of production capacities directly in Azerbaijan. This model 2 / 3
enables CSG to build a long-term industrial presence in strategic foreign markets and, at the same time, to provide partners with access to the technologies and capabilities needed for the development of their own defence industry. The planned joint venture is part of CSG’s broader strategy based on long-term industrial partnerships, technology transfer and the development of local production and servicing capacities in strategic foreign markets.
The ADEX trade fair also serves as an opportunity to showcase products from companies within the CSG group. Exhibitors in Baku include Tatra Export (representing the vehicle manufacturer Tatra Trucks), as well as Excalibur International, Excalibur Army, MSM Group, and AviaNera Technologies. Representatives from Tatra Export are presenting the full portfolio of Tatra vehicles to potential customers – specifically the Force and Tactic model series designed for armed forces. Excalibur International is showcasing the Tadeas 6×6 armored vehicle, built on a Tatra chassis, and the Viking multifunctional mobile combat system designed to destroy targets such as UAVs, aircraft, helicopters, guided missiles, bombs, and precision-guided munitions at low or extremely low altitudes, as well as land and naval targets. Also on display are the ReGuard compact mobile 3D radar for air defense systems capable of detecting and tracking drones with a small radar cross-section and the CM-70 Spear – an advanced, cost-effective C-UAS guided interceptor designed to destroy UAVs.
Excalibur Army is presenting the modern Morana 155mm gun-howitzer in Baku; this system utilizes a highly mobile Tatra chassis and complies with all NATO standards for artillery systems and ammunition. AviaNera Technologies is exhibiting the MTF4000 series engine, designed for modern defense platforms such as cruise missiles, target drones, and anti-ship missiles. In Baku, the MSM Group is showcasing 155mm and 122mm artillery ammunition, as well as various types of 120mm and 105mm tank ammunition – standards for modern NATO main battle tanks and artillery systems. Also on display are 122mm unguided rockets for Grad-type launchers, medium-caliber 30×165mm ammunition, and mortar rounds in 60mm, 81mm, and 120mm calibers.
Attachment
30 September 2026
LEI: 2138003QW2ZAYZODBU23
WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (THE “ISSUER”)
(a public company incorporated with limited liability in Ireland)
1) WISDOMTREE S&P 500 3X DAILY LEVERAGED (ISIN: IE00B7Y34M31)
2) WISDOMTREE NASDAQ 100 3X DAILY LEVERAGED (ISIN: IE00BLRPRL42)
3) WISDOMTREE MAGNIFICENT 7 3X DAILY LEVERAGED (ISIN: XS3091654114)
4) WISDOMTREE PHLX SEMICONDUCTOR 3X DAILY LEVERAGED (ISIN: XS3091657729)
(TOGETHER THE “FS AFFECTED SECURITIES”)
5) WISDOMTREE S&P 500 3X DAILY SHORT (ISIN: IE00B8K7KM88)
6) WISDOMTREE NASDAQ 100 3X DAILY SHORT (ISIN: IE00BLRPRJ20)
7) WISDOMTREE MAGNIFICENT 7 3X DAILY SHORT (ISIN: XS3091657307)
8) WISDOMTREE PHLX SEMICONDUCTOR 3X DAILY SHORT (ISIN: XS3091646797)
(THE “SBR AFFECTED SECURITIES”, TOGETHER WITH THE FS AFFECTED SECURITIES, THE “AFFECTED SECURITIES”)
NOTIFICATION OF CHANGE OF THE STOCK BORROW RATE AND FUNDING SPREAD OF THE AFFECTED SECURITIES
Terms not defined in this notice shall have the meaning ascribed to them in the Issuer’s Base Prospectus dated 22 April 2026.
BNP Paribas acts as Swap Provider for the Affected Securities.
As permitted under paragraph 2.2(iii) of Annex A of the Conditions of the Affected Securities, the Swap Provider has notified the Issuer of its intention to amend i) the Funding Spread in respect of the FS Affected Securities and ii) Stock Borrow rate in respect of the SBR Affected Securities (the “Rate Changes”).
The Rate Changes are detailed at Annex 1 hereto.
The Trustee, the Manager and the Issuer have entered into omnibus amendment deed to amend the Supplemental Trust Deeds relating to the Affected Securities to effect the Rate Changes (the “Affected Securities Amendments”). The effective date of the Affected Securities Amendments shall be 1 October 2026.
For further information, please contact: europesupport@wisdomtree.com
Annex 1
The Rate Changes
FS Affected Securities
| (A) Primary Ticker | (B) Name of Impacted Security | (C) ISIN | (F) Current Funding Spread |
(G) New Funding Spread |
|
| 1 | 3USL | WisdomTree S&P 500 3x Daily Leveraged | IE00B7Y34M31 | 1.2450% | 1.0020% |
| 2 | QQQ3 | WisdomTree NASDAQ 100 3x Daily Leveraged | IE00BLRPRL42 | 1.2450% | 1.0020% |
| 3 | 3MG7 | WisdomTree Magnificent 7 3x Daily Leveraged | XS3091654114 | 1.2450% | 1.0020% |
| 4 | 3SEM | WisdomTree PHLX Semiconductor 3x Daily Leveraged | XS3091657729 | 1.2450% | 1.0020% |
SBR Affected Securities
| (A) Primary Ticker | (B) Name of Impacted Security | (C) ISIN | (D) Current Stock Borrow Rate | (E) New Stock Borrow Rate | |
| 1 | 3USS | WisdomTree S&P 500 3x Daily Short | IE00B8K7KM88 | 0.1150% | 0.3580% |
| 2 | QQQS | WisdomTree NASDAQ 100 3x Daily Short | IE00BLRPRJ20 | 0.1150% | 0.3580% |
| 3 | 3M7S | WisdomTree Magnificent 7 3x Daily Short | XS3091657307 | 0.1150% | 0.3580% |
| 4 | SC3S | WisdomTree PHLX Semiconductor 3x Daily Short | XS3091646797 | 0.1150% | 0.3580% |
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o
كيوتو، اليابان–(BUSINESS WIRE)–بدأت شركة .Murata Manufacturing Co., Ltd (المدرجة في بورصة طوكيو تحت الرمز:6981) (الرقم التعريفي الدولي للأوراق المالية: JP3914400001) الإنتاج التجاري لسلسلة LLD، وهي أصغر مكثفات سيراميكية متعددة الطبقات (MLCC) ثلاثية الأطراف منخفضة الحث المكافئ (ESL) في العالم*. بأبعاد تبلغ 0201 بوصة فقط (0.6 × 0.3 مم)، تعمل المنتجات الجديدة على تقليص مساحة التركيب بنسبة 64% تقريباً مقارنةً بأصغر منتج سابق من Murata بمقاس 0402 بوصة (1.0 × 0.5 مم)، مما يوفر مساحة قيمة لوحة الدوائ
SWORDS, Ireland–(BUSINESS WIRE)–Trane Technologies (NYSE: TT), a global climate innovator, today announced the successful laboratory demonstration of the industry’s first 800-volt direct current (800 VDC) cooling architecture designed to support the mission-critical energy and thermal demands of next-generation AI factories and gigawatt-scale data centers. First validated on a high-efficiency chiller platform, the proof-of-concept demonstrates the performance, efficiency and design advantages
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o
CANTON, Mass.–(BUSINESS WIRE)–This week at the MEDITECH LIVE leadership summit, healthcare organizations using MEDITECH’s Traverse Exchange interoperability network highlighted significant benefits gained since implementing the network’s new Consolidated Patient Summary. Unveiled at last year’s summit, the enhanced workflow has seen swift adoption among clinicians, providing care teams with faster access to critical patient information, reducing duplicate testing, and supporting more informed